SAN DIEGO,CA (Oct. 21, 2020) ­– Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, announced today initiation of a Phase 2 clinical trial of OXE103 for treating concussion.

Concussion Alliance Interviews the CEO of Oxeia, Michael Wyand and co-founder and chief scientific officer, Dr. Vishal Bansal on the company’s work developing a drug treatment for concussion.

Oxeia's Chief Scientific Officer Vishal Bansal shared his knowledge of the science behind concussions, as well as his hopes for future treatments on "Recovery Now," on the Brain Injury Network. Dr. Bansal told the host, Kim Justus, that the drug Oxeia is developing for treating concussions is targeting the 20% of concussion sufferers who don't recover in 28 days from their injury.

Concussions are a serious health problem in the military. In January, 2020, 109 US servicemen in Iraq suffered traumatic brain injury from Iranian airstrikes. But this is just the latest occurrence; in the last 9 years over 413,000 troops were diagnosed with TBI.

In this article, Oxeia co-founder and chief scientific officer, Vishal Bansal, calls on Congress, the Pentagon, and the medical establishment to increase their commitment to finding an effective treatment to protect our proud members of the military.

Fortune contributor Michael Lev-Ram acknowledges Richard Sherman’s numerous accomplishments in football but Lev-Ram devotes more ink telling of Sherman's role as a tech investor.

Lev-Ram observes that Sherman is emerging as a Silicon Valley venture capitalist with a purpose, finding new solutions to address health and safety issues in sports. He gives a special call-out to Sherman’s role with Oxeia Biopharmaceuticals, "a drug company that’s experimenting with a drug that mitigates the effect of concussions right after they happen."

Oxeia Biopharmaceuticals' CEO Michael Wyand, DVM, PhD, will participate in a panel discussion on redefining therapeutics areas and new technology paradigms at the Genesis 2019 Life Sciences Conference in London in December. Oxeia is preparing for the launch of Phase 2 human clinical studies for its therapeutic drug to treat concussions.

49ers star Richard Sherman is betting on software and against concussions as he dives into start-ups. One of the startups is Oxeia Biopharmaceuticals, which is developing a concussion drug that would treat the immediate symptoms and the underlying damage.

Seniors suffer from concussions at far higher rates than any other group. Oxeia Biopharmaceuticals is working on a drug that will treat concussions. They have completed Phase 1 trials and are preparing for human trials.

San Francisco 49ers cornerback and Oxeia board member Richard Sherman stops by the Tiki and Tierney Show to talk about concussions and Oxeia's research.

SF 49er and Oxeia board member Richard Sherman speaks his mind about the NFL's concussion policy in his San Francisco Chronicle op-ed. Tells readers concussion medicines are under development.

S+P: Leading market analysis publication interviews Oxeia CEO Michael Wyand about how Oxeia works, clinical trials, and anticipated market.

Oxeia Biopharmaceuticals Inc. announces the appointment of Michael Wyand, DVM, PhD as Chief Executive Officer. Dr. Wyand will also join Oxeia’s Board of Directors.